BACKGROUND: The aim of this study was to determine the dose-response relationship for losartan, 2.5 to 100 mg, and to assess the safety and tolerability of losartan in hypertensive children 6 to 16 years of age. METHODS: This was a multicenter, randomized, double-blind, dose-response study. In Period 1, a total of 175 patients were stratified by weight (<50 kg and >/=50 kg) and randomized to one of three dose groups by stratum (low, 2.5/5.0 mg; middle, 25/50 mg; or high, 50/100 mg) for 3 weeks. The ratio of the three dose levels for both weight strata was 1:10:20. In Period 2, patients in each dose group were randomized to continue the same treatment or placebo washout for 2 additional weeks. RESULTS: In Period 1, sitting trough diastolic blood pressure (DBP) decreased in a dose-dependent manner (P < .0001). At week 3, changes in DBP from baseline in the low-, middle-, and high-dose groups were -6.0 mm Hg, -11.7 mm Hg, and -12.2 mm Hg, respectively. In Period 2, DBP increased significantly in patients who switched from middle- and high-dose losartan to placebo (mean increase 6.0 mm Hg, P = .003) relative to DBP in patients who remained on active treatment; however, these levels remained stable in those patients who switched from low-dose losartan to placebo (mean increase 1.1 mm Hg, P = .628). CONCLUSIONS: In hypertensive children 6 to 16 years of age, losartan given once daily reduced blood pressure in a dose-dependent fashion. A once-daily starting dose of losartan, 0.75 mg/kg (maximum 50 mg) effectively lowered DBP within 3 weeks. Losartan up to a dosage of 1.44 mg/kg (maximum 100 mg) once daily is generally well tolerated.
RCT Entities:
BACKGROUND: The aim of this study was to determine the dose-response relationship for losartan, 2.5 to 100 mg, and to assess the safety and tolerability of losartan in hypertensivechildren 6 to 16 years of age. METHODS: This was a multicenter, randomized, double-blind, dose-response study. In Period 1, a total of 175 patients were stratified by weight (<50 kg and >/=50 kg) and randomized to one of three dose groups by stratum (low, 2.5/5.0 mg; middle, 25/50 mg; or high, 50/100 mg) for 3 weeks. The ratio of the three dose levels for both weight strata was 1:10:20. In Period 2, patients in each dose group were randomized to continue the same treatment or placebo washout for 2 additional weeks. RESULTS: In Period 1, sitting trough diastolic blood pressure (DBP) decreased in a dose-dependent manner (P < .0001). At week 3, changes in DBP from baseline in the low-, middle-, and high-dose groups were -6.0 mm Hg, -11.7 mm Hg, and -12.2 mm Hg, respectively. In Period 2, DBP increased significantly in patients who switched from middle- and high-dose losartan to placebo (mean increase 6.0 mm Hg, P = .003) relative to DBP in patients who remained on active treatment; however, these levels remained stable in those patients who switched from low-dose losartan to placebo (mean increase 1.1 mm Hg, P = .628). CONCLUSIONS: In hypertensivechildren 6 to 16 years of age, losartan given once daily reduced blood pressure in a dose-dependent fashion. A once-daily starting dose of losartan, 0.75 mg/kg (maximum 50 mg) effectively lowered DBP within 3 weeks. Losartan up to a dosage of 1.44 mg/kg (maximum 100 mg) once daily is generally well tolerated.
Authors: Giacomo D Simonetti; Rodo O von Vigier; Martin Konrad; Mattia Rizzi; Emilio Fossali; Mario G Bianchetti Journal: Pediatr Nephrol Date: 2006-06-27 Impact factor: 3.714
Authors: Mark J Osborn; Beau R Webber; Ronald T McElmurry; Kyle D Rudser; Anthony P DeFeo; Michael Muradian; Anna Petryk; Benedikt Hallgrimsson; Bruce R Blazar; Jakub Tolar; Elizabeth A Braunlin Journal: J Inherit Metab Dis Date: 2016-10-14 Impact factor: 4.982
Authors: Perdita Taylor-Zapata; Carissa M Baker-Smith; Gilbert Burckart; Stephen R Daniels; Joseph T Flynn; George Giacoia; Dionna Green; Aaron S Kelly; Mona Khurana; Jennifer S Li; Charlotte Pratt; Elaine M Urbina; Anne Zajicek Journal: Pediatrics Date: 2019-05 Impact factor: 7.124
Authors: Nicholas J A Webb; Chun Lam; Tom Loeys; Shahnaz Shahinfar; Juergen Strehlau; Thomas G Wells; Emanuela Santoro; Denise Manas; Gilbert W Gleim Journal: Clin J Am Soc Nephrol Date: 2010-01-14 Impact factor: 8.237
Authors: Thomas G Wells; Douglas L Blowey; Janice E Sullivan; Jeffrey Blumer; Joseph R Sherbotie; Saeheum Song; Shashank Rohatagi; Reinilde Heyrman; Daniel E Salazar Journal: Paediatr Drugs Date: 2012-12-01 Impact factor: 3.022
Authors: Daniel K Benjamin; P Brian Smith; Pravin Jadhav; Jogarao V Gobburu; M Dianne Murphy; Vic Hasselblad; Carissa Baker-Smith; Robert M Califf; Jennifer S Li Journal: Hypertension Date: 2008-03-10 Impact factor: 10.190